Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 220

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 220
---
,794 6,520 20297,031 6,423 Thereafter9,160 8,760 Total$38,955 38,487 Less:Present value adjustment (9,694)Total $28,793 The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows: June 30, 2025December 31, 2024Weighted average remaining lease term5.3 years5.9 yearsWeighted average discount rate9.5%10.1%CommitmentsWe have entered into material purchase commitments with commercial manufacturers for the supply of HEPLISAV-B. As of June 30, 2025, our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B totaled $79.1 million, which are expected to be paid through 2029. In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.We also rely on and have entered into agreements with research institutions, contract research organizations and clinical investigators as well as clinical material manufacturers. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period. ContingenciesFrom time to time, we may be involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in substantial damages, fines, penalties or orders requiring a change in our business practices, which could in the future materially and adversely